| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print December 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lipid Metabolism, JM/HNRCA at Tufts Univaresity, Boston, MA 02111
Corresponding Author: bela.asztalos{at}tufts.edu
Our purpose was to compare HDL subpopulations, as determined by non-denaturing two-dimensional gel-electrophoresis followed by immunoblotting for apolipoproteins A-I, A-II, A-IV, C-I, C-II, C-III, and E, in heterozygous, compound heterozygous, and homozygous subjects for CETP-deficiency and controls. Heterozygotes, compound heterozygotes, and homozygotes had CETP mass that were 30%, 63%, and over 90% lower, and HDL-C values that were 64%, 168%, and 203% higher than in controls, respectively. Heterozygotes had about 50% lower pre
Revised on November 10, 2003
Accepted on November 19, 2003
Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency
-1 and more than two-fold higher levels of 
-1 and pre-1 particles compared to controls. Three out of five heterozygotes had -1 particles that contained apoA-II, which was not seen in controls. Compound heterozygotes and homozygotes had very large particles not observed in controls and heterozygotes. These particles contained apoA-I, apoA-II, apoCs, and apoE. Moreover, these subjects did not have decreased concentrations of pre-1 particles. Our data are consistent with the concept that CETP-deficiency results in the formation of very large unique HDL particles containing all the major HDL apolipoproteins except for apoA-IV. We hypothesize that the HDL subpopulation profile of heterozygotes with high LpA-I -1 levels is anti-atherogenic, while this might not be the case for compound heterozygotes and homozygotes with very low or no CETP mass and large undifferentiated HDL particles
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. D. Santos, E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang, R. A. Hegele, L. R. C. Martinez, M. H. Miname, C. E. Rochitte, P. L. Da Luz, et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency J. Lipid Res., February 1, 2008; 49(2): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P F Dullaart, A. K Groen, G. M Dallinga-Thie, R. de Vries, W. J Sluiter, and A. van Tol Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol Eur. J. Endocrinol., January 1, 2008; 158(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Settasatian, P. J. Barter, and K.-A. Rye Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein J. Lipid Res., January 1, 2008; 49(1): 115 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guerin, W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 148 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Asztalos, E. J. Schaefer, K. V. Horvath, S. Yamashita, M. Miller, G. Franceschini, and L. Calabresi Role of LCAT in HDL remodeling: investigation of LCAT deficiency states J. Lipid Res., March 1, 2007; 48(3): 592 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. van der Steeg, G. K. Hovingh, A. H. E. M. Klerkx, B. A. Hutten, I. C. Nootenboom, J. H. M. Levels, A. van Tol, G. M. Dallinga-Thie, A. H. Zwinderman, J. J. P. Kastelein, et al. Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians J. Lipid Res., March 1, 2007; 48(3): 674 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Rye, R. Bright, M. Psaltis, and P. J. Barter Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E J. Lipid Res., May 1, 2006; 47(5): 1025 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Asztalos, D. Collins, L. A. Cupples, S. Demissie, K. V. Horvath, H. E. Bloomfield, S. J. Robins, and E. J. Schaefer Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2185 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al. Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
